TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00534638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses
Study: NCT01551797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500 mg
Description: Standard Paracetamol formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol Sustained Release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 750 mg
Description: Paracetamol Sustained Release formulation
Study: NCT04962529

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
Study: NCT01076244

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally Invasive Lumbar Decompression
Description: This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
Study: NCT03613389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral topical vitamin E
Description: Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
Study: NCT01561677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway pressure-RESPIRONICS
Description: obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous Positive Airway pressure-RESPIRONICS
Description: inefficient Continuous Positivie Airway pressure
Study: NCT04802889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scanning electron microscopy
Description: scanning electron microscopy of the сentral retina and preretinal structures
Study: NCT02271984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study: NCT02439788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GINAKIT Cells
Description: * Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future.
Study: NCT03494049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veil sparring HoLEP
Description: Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard HoLEP
Description: Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
Study: NCT01457638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior turbinate surgery
Description: During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No iInferior turbinate surgery
Description: During rhinoseptoplasty no intervention is done in inferior turbinates
Study: NCT04342143

Intervention type: DEVICE
Intervention: Blood pressure and ultrasound assessment
Description: No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
Study: NCT02772939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Description: Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
Study: NCT05034406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine
Description: 6 mL of 2% lidocaine injected at the trocar insertion site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Description: 6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
Study: NCT04385576

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation Box
Description: Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
Study: NCT02622555

Intervention type: DRUG
Intervention: Mirabegron
Description: Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
Study: NCT04091126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
Study: NCT03513926

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure
Study: NCT02236338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the Incompetent Greater Saphenous Vein
Description: For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the Incompetent Greater Saphenous Vein
Description: For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFAST radiofrequency catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVLT 980nm diode laser system
Study: NCT02659852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: side by side
Description: Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent in stent
Description: After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
Study: NCT03093909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
Study: NCT04059601

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance cholangiography
Description: preoperative MRCP in acute cholecystitis before cholecystectomy

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative cholangiography
Description: Intraoperative cholangiography in acute cholecystitis during cholecystectomy
Study: NCT00991588

Intervention type: PROCEDURE
Intervention: PCL, posterolateral reconstruction
Description: The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
Study: NCT02159716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso
Description: CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso
Description: CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso
Description: CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
Study: NCT01253720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE CALL/Fit4Life
Description: The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach
Study: NCT03082274

Intervention type: DIAGNOSTIC_TEST
Intervention: ConfirmMDx
Description: ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.

Intervention type: DIAGNOSTIC_TEST
Intervention: SelectMDx
Description: SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
Study: NCT00760058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ IOL
Description: Replacement of natural crystalline lens in cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis® Aspheric intraocular lens
Description: Replacement of natural crystalline lens in cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akreos® MI60 intraocular lens
Description: Replacement of natural crystalline lens in cataract surgery
Study: NCT00421174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus corticosteroid
Description: Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
Study: NCT01415466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto
Description: tablet, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmetec
Description: tablet, 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto, Olmetec
Description: tablet, 20mg and 40mg
Study: NCT02116803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib
Description: Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
Study: NCT02966379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation
Description: Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point
Study: NCT03513926

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure
Study: NCT01287325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 100 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02614378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air insufflation
Description: modulated air insufflation of the ear canal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no air will be introduced in the ear canal
Study: NCT01245140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alitretinoin
Description: to receive verum (20 patients)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to receive placebo (10 patients)
Study: NCT05528523

Intervention type: OTHER
Group type: OTHER
Intervention: Writing a clinical narrative
Description: The participants had to write a clinical narrative regarding a significant encounter with a patient.
Study: NCT04184453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone treated
Description: Deferiprone (25 mg/kg/day) was given to the enrolled patients.
Study: NCT02961257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: * Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: * Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
Study: NCT04508855

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Switch from direct oral anticoagulants to low molecular weight heparin
Study: NCT03177720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
Study: NCT01673022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Green
Description: IC Green
Study: NCT01686139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABMD-MSC
Description: 10-20 x 10\^6 cells/20mL